Sep 17, 2012 by Brian Orelli, PhDThis Obesity Drug Hits the Market, but Check Your ExpectationsVIVUS launches Qsymia.
Sep 16, 2012 by Brian Orelli, PhDInvest Better: It's OK to Not UnderstandSometimes, passing on a stock is the best option.
Sep 13, 2012 by Brian Orelli, PhDChallenges Loom for This New DrugSanofi's Aubagio needs to find a niche.
Sep 12, 2012 by Brian Orelli, PhDIs This Drug Taking on Water?FDA gives Cornerstone's lixivaptan a mixed review.
Sep 11, 2012 by Brian Orelli, PhDWhy Risk Is Always Relative in BiotechAfter ditching stem cells, Geron's imetelstat doesn't work.
Sep 11, 2012 by Brian Orelli, PhDWhat to Make of This FDA RejectionNavidea's Lymphoseek gets rejected by the FDA for manufacturing reasons.
Sep 10, 2012 by Brian Orelli, PhD"Better Than Nothing" Doesn't Cut It for ZalicusZalicus' Synavive beats placebo, but not an active comparator.
Sep 9, 2012 by Brian Orelli, PhDThis Failed Drug Bet Is Business as UsualLilly made a high-risk bet, but that's OK.
Sep 7, 2012 by Brian Orelli, PhDDoes This Pharma Deal Make Sense?Jazz Pharmaceuticals slims down by selling its women's health business.
Sep 6, 2012 by Brian Orelli, PhDBig Demand for (Free) Obesity DrugsOrexigen enrolls its Contrave trial early.
Sep 5, 2012 by Brian Orelli, PhDPain-Free Pipeline ProgressZalicus moves its nerve-pain drug into phase 2 development.
Sep 5, 2012 by Brian Orelli, PhDIs This Biotech's Shortened Study Good Enough for Approval?BioSante stops its long-term safety study early.
Sep 4, 2012 by Brian Orelli, PhDA Once-in-a-Blue-Moon FDA ApprovalMedivation gets a rare quick approval.
Aug 31, 2012 by Brian Orelli, PhDReading Between the FDA LinesA canceled advisory panel seems like a good sign for Exelixis' cabozantinib.
Aug 31, 2012 by Brian Orelli, PhDA Good Start on the Biosimilar FrontTeva gets a generic of a biologic approved.
Aug 31, 2012 by Brian Orelli, PhDConverting the DissatisfiedSeems like a winning strategy for launching a drug.
Aug 31, 2012 by Brian Orelli, PhDThe Biggest Little Biotechs in the WorldCompanies Reno, NV could be proud of.
Aug 30, 2012 by Brian Orelli, PhDVertex Gets Some Ratty NewsSide effects in rats might not be a problem for Vertex's Kalydeco.
Aug 30, 2012 by Brian Orelli, PhDThis Dividend Stock Needs a Hit, but This Isn't ItEli Lilly's schizophrenia drug fails again.
Aug 30, 2012 by Brian Orelli, PhDThis Drug Is Getting Some Negative ATTENTIONArQule falls as a side effect is seen in a Japanese trial of tivantinib.
